In Uskudar’s study, the average period of anti-TNF agent administration in patients who experienced new-onset IBD was 15.14 ± 8.5 months (median 12 months) while in Braun’s study the new onset or flare of IBD occurred after a mean of 242 days (range 57–545 days) or 8.1 months of treatment with ETN and 1 year of treatment with IFX [24,25]. The gene discussed is TNF; the disease is inflammatory bowel disease.